Kartik Chandran 1 Curriculum vitae for Kartik Chandran, PhD Contact Information Albert Einstein College of Medicine Department of Microbiology and Immunology 403 Golding Building, 1300 Morris Park Ave. Bronx, NY 10461 E-mail: [email protected] Alt E-mail: [email protected] Phone: 718-430-8851 Web sites: https://www.chandranlab.org https://www.einstein.yu.edu/faculty/10768/kartik-chandran/ Education Lafayette College, Easton, PA, 1991–1995 B.S. in Biochemistry (summa cum laude) University of Wisconsin-Madison, Madison, WI, 1995–2001 Ph.D in Biochemistry Mentor: Max L. Nibert, M.D., Ph.D. Post-graduate Training Dept. of Microbiology & Molecular Genetics, Harvard Medical School, Boston, MA, 2001– 2003 Research Fellow Mentor: Max L. Nibert, M.D., Ph.D. Dept. of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 2003–2006 Research Fellow Mentor: James M. Cunningham, M.D. Professional Employment Dept. of Microbiology & Immunology, Albert Einstein College of Medicine, Bronx, NY, 2007– present 2007–2012 Assistant Professor of Microbiology and Immunology 2012–2017 Associate Professor of of Microbiology and Immunology Kartik Chandran 2 2013– Harold and Muriel Block Faculty Scholar in Virology 2017– Professor of Microbiology and Immunology (with tenure) Professional Society Memberships American Society for Virology, American Society for Microbiology Awards and Honors 1992 CRC Freshman Chemistry Prize, Lafayette College 1992 Phi Beta Kappa Eugene P. Chase Prize for scholarship, Lafayette College 1994 Woods Hole Oceanographic Institution Summer Student Fellowship, Woods Hole, MA 1994 Phi Beta Kappa national honor society 1995 American Chemical Society Award to the Outstanding Senior Chemistry Major, Lafayette College 1996 Wisconsin Alumni Research Foundation Fellowship, UW-Madison 1996–2001 Howard Hughes Medical Institute Predoctoral Fellowship in the Biological Sciences, UW-Madison 2001–2002 Bernard N. Fields Postdoctoral Fellowship, Harvard Medical School 2004–2005 Career Development Award, New England Research Center of Excellence in Biodefense and Emerging Infectious Diseases (NERCE/BEID), Boston, MA 2013–2018 Irma T. Hirschl/Monique Weill-Caulier Research Award, Albert Einstein College of Medicine 2013– Harold and Muriel Block Faculty Scholar in Virology Administrative service Committee Service (Einstein) 2007–2012 Member | Graduate Admissions committee 2009–2010 Senator | Einstein Faculty Senate 2012–2013 Member | Committee on Appointments and Promotions (Associate Professor) 2013–2014 Co-Chair | Committee on Appointments and Promotions (Associate Professor) 2013– Member | Senate Committee on Fiscal Affairs 2014–2015 Chair | Committee on Appointments and Promotions (Associate Professor) 2014–2019 Co-Director | NIH training grant, Geographic Medicine and Emerging Infections (Einstein) 2009–2010 Senator | Einstein Faculty Senate 2018– Assistant director | NIH training grant, Geographic Medicine and Emerging Infections (Einstein) Kartik Chandran 3 Teaching Einstein graduate and medical schools 2013– Course leader and lecturer | Viruses (annual or biennial course offering) 2018– Lecturer | Molecular Cell Biology (annual course offering) 2015 Lecturer | Immunology 2010– Lecturer | Mechanisms of Disease (annual course offering) 2010 Lecturer | Microbiology and Infectious Diseases (2nd year medical school course) 2008– Lecturer | Microbial Pathogenesis (annual or biennial course offering) 2007– Lecturer | Viruses (annual or biennial course offering) External 2020 Lecturer | Human Viral Diseases (Umeå University, Sweden) 2019 Lecturer | Advanced Virology (Icahn School of Medicine at Mount Sinai) 2017 Lecturer | Advanced Virology (Icahn School of Medicine at Mount Sinai) 2014 Lecturer | Molecular Biology of Animal Viruses (Yale University) Research Patents and patent applications US Patent 8,232,240 Inhibitors of enveloped virus infectivity US Patent 9,234,885 Methods and assays for treating Filoviridae infections US Patent 9,346,875 Therapy for filovirus infection US Patent 9,452,992 Small molecule inhibitors of Ebola and Lassa fever viruses US Patent 9,676,763 Method of treating Ebola US Patent 10,081,669 Therapy for filovirus infection US Patent 10,105,433 Methods and assays for treating hantavirus infections US Patent 10,377,815 Bispecific antibodies and fusion proteins that bind to EBOV and NPC1 US Patent 10,435,461 Therapy for filovirus infection US Patent 10,836,810 Monoclonal antibodies and cocktails for treatment of Ebola infections US App 2019/0292165 Broad spectrum inhibitors of filoviruses Extramural grants Current 2020–2025 NIH R01 AI152246; PI: Chandran | Co-PI: Jason McLellan (U Texas at Austin) Structure-based vaccine design for CCHFV 2020–2024 NIH R01 GM087544; PI: Howard Hang (Scripps) | Role: Co-investigator Studies on protein lipidation Kartik Chandran 4 2020–2021 NIH UL1 TR003167-02S2; PI: David McPherson et al. (U Texas HSC Houston) | Role: Co-investigator Convalescent plasma to limit coronavirus associated complications 2020–2021 NIH UL1 TR002736-03S1; PI: Ralph Sacco (U Miami) | Role: Co-investigator Convalescent plasma to limit coronavirus associated complications 2020–2021 NIH UL1 TR002556-04S1; PI: Marla Keller et al. (Einstein) | Role: Co-investigator Convalescent plasma to limit coronavirus associated complications 2019–2024 NIH U19 AI142777; PI: Chandran Prometheus: A Platform for Rapid Development of Human Antibody Based Therapeutics and Prophylactics against Emerging Viral Threats 2018–2023 NIH R44 AI136272; PI: Larry Zeitlin (Mapp Bio) | Role: Co-investigator Development Of highly potent human monoclonal for RSV Immunoprophylaxis 2018–2023 NIH T32 AI070117; PI: Louis Weiss (Einstein) | Role: Assistant Director Training Program in Geographic Medicine and Emerging Infections 2017–2021 NIH R01 AI134824; PI: Chandran Host-virus interactions in the control of filovirus entry 2017–2022 NIH R01 AI132633; PI: Chandran Dissecting the receptor-mediated infection mechanisms of hantaviruses 2017–2022 NIH R01 AI132256; PI: Chandran A “Trojan Horse” bispecific antibody strategy for broad filovirus therapeutics 2017–2022 NIH R01 AI125462; PI: Jonathan Lai (Einstein) | Role: Coinvestigator Engineered, multispecific antibodies as broad anti-filovirus therapeutics 2017–2021 NIH R01 AI132204; PI: Javad Aman (Integrated Biotherapeutics) | Role: Co- investigator Rationally designed pan-ebolavirus vaccine 2017–2020 NIH R42 AI122403; PI: Javad Aman (Integrated Biotherapeutics) | Role: Co- investigator Broadly protective bispecific antibodies for treatment of Ebola virus disease 2016–2021 NIH R01 AI125462; PI: Jonathan R. Lai | Role: Co-investigator Engineered antibodies as anti-filovirus therapeutics 2016–2021 NIH R01 PI: M. Javad Aman (Integrated Biotherapeutics) | Role: Co- investigator Evolution of anti-filovirus B cell responses and mechanisms of protection Kartik Chandran 5 2016–2020 US Defense Threat Reduction Agency HDTRA1-14-CHEM-BIO-CBM03; PI: Terry Bowlin (Microbiotix) | Role: Co-investigator Optimization of broad-spectrum inhibitors of filovirus infection that antagonize the NPC1-GP interaction Previous 2018–2019 NIH R43 AI136188; PI: Grace Liu (Microbiotix) | Role: Co-investigator Inhibitors of virus glycoprotein-LAMP1 receptor Binding for Lassa Virus Therapy 2014–2019 NIH T32 AI070117; PI: Kami Kim (Einstein) | Role: Co-Director Training Program in Geographic Medicine and Emerging Infections 2014–2019 NIH U19 AI109762; PI: Erica Saphire (Scripps) | Role: Core Lead Consortium for Immunotherapeutics against Viral Hemorrhagic Fevers 2013–2018 Irma T. Hirschl/Monique Weill-Caulier Research Award; PI: Chandran 2012–2017 NIH R33 AI102240; PI: Chandran Discovery and evaluation of anti-filovirus therapeutics targeting NPC1 2012–2017 NIH R01 AI101436; PI: Chandran Mechanism of receptor-mediated entry and infection by filoviruses 2010–2015 NIH R01 AI088027; PI: Chandran Mechanisms of ebolavirus and marburgvirus entry into cells 2013–2014 US Defense Threat Reduction Agency; PI: Terry Bowlin (Microbiotix) | Role: Co- investigator Developing inhibitors of filovirus infection targeting the viral receptor NPC1 2010–2015 NIH R01 AI090249; PI: Jonathan R. Lai (Einstein) | Role: Co-investigator Targeting viral envelope glycoproteins with synthetic antibodies 2009–2011 NIH R21 AI082437; PI: Chandran Targets of novel Ebola virus entry inhibitors 2008–2010 NIH K22 AI074908; PI: Chandran Role of endosomal cysteine proteases in Ebola and Marburg virus entry Kartik Chandran 6 Original Peer-reviewed Research Communications *Corresponding/co-corresponding author §First/co-first author Albert Einstein College of Medicine (present–2007) 1. Fels JM, Bortz RH, Alkutkar T, Mittler E, Jangra RK, Spence JS, Chandran K*. 2021. A glycoprotein mutation that emerged during the 2013-2016 Ebola virus epidemic alters proteolysis and accelerates membrane fusion. mBio. In press. 2. Yoon HA, Bartash R, Gendlina I, Rivera J, Nakouzi A, Bortz Iii RH, Wirchnianski AS, Paroder M, Fehn K, Serrano-Rahman L, Babb R, Sarwar UN, Haslwanter D, Laudermilch E, Florez C, Dieterle ME, Jangra RK, Fels JM, Tong K, Mariano MC, Vergnolle O, Georgiev GI, Herrera NG, Malonis RJ, Quiroz JA, Morano NC, Krause GJ, Sweeney JM, Cowman K, Allen SA, Annam J, Applebaum A, Barboto D, Khokhar A, Lally BJ, Lee A, Lee M, Malaviya A, Sample R, Yang XA, Li Y, Ruiz RE, Thota R, Barnhill J, Goldstein DY, Uehlinger J, Garforth SJ, Almo SC, Lai JR, Reyes Gil M, Fox AS, Chandran K*, Wang T, Daily JP, Pirofski LA. 2021. Treatment of Severe COVID-19 with Convalescent